Susquehanna Fundamental Investments LLC Buys Shares of 53,938 Merus (NASDAQ:MRUS)

Susquehanna Fundamental Investments LLC bought a new stake in Merus (NASDAQ:MRUS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 53,938 shares of the biotechnology company’s stock, valued at approximately $2,268,000. Susquehanna Fundamental Investments LLC owned approximately 0.08% of Merus at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN increased its stake in shares of Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 300 shares during the last quarter. Avior Wealth Management LLC bought a new position in Merus in the fourth quarter valued at about $76,000. HighTower Advisors LLC raised its stake in Merus by 10.9% during the fourth quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 789 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Merus in the fourth quarter worth about $347,000. Finally, Harbour Capital Advisors LLC acquired a new stake in shares of Merus in the 4th quarter valued at approximately $360,000. Institutional investors own 96.14% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on MRUS shares. Guggenheim reissued a “buy” rating and issued a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, March 3rd. Bank of America cut their price objective on Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, March 10th. William Blair reaffirmed an “outperform” rating on shares of Merus in a report on Monday. Finally, Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target on the stock. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $85.31.

Merus Price Performance

NASDAQ MRUS opened at $45.05 on Wednesday. The stock has a market capitalization of $3.11 billion, a P/E ratio of -11.41 and a beta of 1.02. The business has a 50 day simple moving average of $44.08 and a 200 day simple moving average of $44.62. Merus has a one year low of $33.19 and a one year high of $61.61.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Equities analysts expect that Merus will post -3.85 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.